Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

Why are Starbucks baristas striking over dress code? How will Walmart’s tariff hike impact prices? Why did UnitedHealth stock plunge recently? What caused Coinbase’s $400M cyberattack loss? How is Trump’s Middle East tour affecting trade? Why is Dick’s Sporting Goods buying Foot Locker? How are Trump’s tariffs influencing US retailers? What’s behind Japan’s recent economic contraction? Why did Elon Musk’s AI bot mention South Africa?

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

benzinga.com/general/biotech/25/05/45450474/immutep-reports-61-response-rate-in-lung-cancer-trial-with-keytruda-based-triple-combo

Immutep Limited (NASDAQ:IMMP) on Thursday announced additional data from the investigator-initiated INSIGHT-003 trial evaluating a triple combination therapy in front-line non-small cell lung cancer patients consisting of efti administered in conjunction with Merck & Co Inc’s (NYSE:MRK)…

This story appeared on benzinga.com, 2025-05-15 19:50:04.